Alison Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alison Thomas has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Akash Patnaik
University of Chicago, Chicago, IL
69 shared publications - Brian M. Olson
Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia
69 shared publications - Christina Hong
Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia
69 shared publications - Kiranj Chaudagar
University of Chicago 4 Section of Hematology/Oncology, Department of Medicine Chicago, Illinois
69 shared publications - Marguerite Li
Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia
69 shared publications - Raymond Chen
Section of Hematology/Oncology, Departmentof Medicine, University of Chicago, Chicago, Illinois
69 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Androgen deprivation increases the frequency of infiltrating T cells and M1 tumor-associated macrophages in the tumor microenvironment.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Androgen deprivation increases the frequency of infiltrating T cells and M1 tumor-associated macrophages in the tumor microenvironment.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Decreased Rb1 expression correlates with predicted decreased immune infiltration across multiple disease histologies.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Decreased Rb1 expression correlates with predicted decreased immune infiltration across multiple disease histologies.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Pharmacological inhibition of BET family members by JQ-1.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Pharmacological inhibition of BET family members by JQ-1.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
List of antibodies used in experiments
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
List of antibodies used in experiments
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Generation and characterization of growth kinetics of Rb-deficient Myc-CaP cell line.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Generation and characterization of growth kinetics of Rb-deficient Myc-CaP cell line.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
JQ-1 treatment in vivo increases PD-L1 expression on myeloid suppressive cells.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
JQ-1 treatment in vivo increases PD-L1 expression on myeloid suppressive cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
T cell and macrophage depletion studies in mice bearing Myc-CaPWT or Myc-CaPΔRb tumors.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
T cell and macrophage depletion studies in mice bearing Myc-CaPWT or Myc-CaPΔRb tumors.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
JQ-1 does not induce apoptosis at 1 µM concentration that activates non-canonical STING/NF-κB signaling.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
JQ-1 does not induce apoptosis at 1 µM concentration that activates non-canonical STING/NF-κB signaling.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Loss of Rb results in altered gene expression that promotes immune suppression as well as increased Tmem173/STING expression.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade
Loss of Rb results in altered gene expression that promotes immune suppression as well as increased Tmem173/STING expression.